Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study
- PMID: 12621792
Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study
Abstract
Objective: To evaluate the prognostic impact of different clinicopathologic parameters in patients with uterine leiomyosarcoma.
Study design: Twenty-one patients with histologically proven uterine leiomyosarcoma were included in the analysis. Leiomyosarcomas were defined as uterine smooth muscle tumors with > or = 5 mitoses per 10 high-power fields and nuclear atypia and/or necrosis.
Results: The median follow-up time was 47 months; 5-year overall survival was 41%. A univariate Cox model revealed that early tumor stage (P = .00001), age at diagnosis < 50 years (P = .02), absence of vascular space involvement (P = .04), low myometrial invasion (P = .006) and low histologic grade (P = .04) were associated with lengthened overall survival. Adjuvant radiotherapy and/or chemotherapy (P = .1) did not influence overall survival.
Conclusion: Early tumor stage, age at diagnosis < 50 years, absence of vascular space invasion, low myometrial invasion and low histologic grade were parameters of a good prognosis in women with uterine leiomyosarcoma. Adjuvant chemotherapy and/or radiotherapy showed no benefit in these patients.
Similar articles
-
Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases.Gynecol Oncol. 1999 Aug;74(2):196-201. doi: 10.1006/gyno.1999.5436. Gynecol Oncol. 1999. PMID: 10419731
-
Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.Cancer. 2000 Mar 15;88(6):1425-31. Cancer. 2000. PMID: 10717626
-
Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study.Anticancer Res. 2001 Jul-Aug;21(4B):3069-74. Anticancer Res. 2001. PMID: 11712812
-
Treatment of uterine leiomyosarcoma.Obstet Gynecol. 1988 Jun;71(6 Pt 1):845-50. Obstet Gynecol. 1988. PMID: 2453004 Review.
-
[Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy].Bull Cancer. 1997 Jun;84(6):625-9. Bull Cancer. 1997. PMID: 9295866 Review. French.
Cited by
-
Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Leiomyosarcoma: 27 Years of Experience.Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1085-1089. doi: 10.1055/s-0031-1280462. Geburtshilfe Frauenheilkd. 2011. PMID: 27065481 Free PMC article.
-
Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.Clin Cancer Res. 2012 Sep 1;18(17):4633-45. doi: 10.1158/1078-0432.CCR-12-0436. Epub 2012 Jul 20. Clin Cancer Res. 2012. PMID: 22821997 Free PMC article.
-
Primary Ovarian Leiomyosarcoma Is a Very Rare Entity: A Narrative Review of the Literature.Cancers (Basel). 2023 May 28;15(11):2953. doi: 10.3390/cancers15112953. Cancers (Basel). 2023. PMID: 37296915 Free PMC article. Review.
-
Treatment of early uterine sarcomas: disentangling adjuvant modalities.World J Surg Oncol. 2009 Apr 8;7:38. doi: 10.1186/1477-7819-7-38. World J Surg Oncol. 2009. PMID: 19356236 Free PMC article. Review.
-
Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.Wien Klin Wochenschr. 2004 Feb 28;116(4):135-9. doi: 10.1007/BF03040751. Wien Klin Wochenschr. 2004. PMID: 15038405
Publication types
MeSH terms
LinkOut - more resources
Medical